Current MTB diagnostics methods require weeks to deliver a definitive result. Delayed result reporting can lead to patients being left untreated or placed on ineffective therapies. If untreated, patients may continue to spread MTB to others in the community increasing the disease burden.
Great challenges face the global community, including United States, with the worldwide re-emergence of TB and increased number of multi-drug resistant (MDR) and emergence of extensively drug-resistant (XDR) TB strains. The need for fast and accurate TB diagnosis with indication for the drug resistance is greater than ever.
Xpert MTB/RIF, on-demand molecular testing — an ideal solution:
Unprecedented sensitivity for detecting MTB — even in smear-negative, culture-positive specimens
Simultaneous detection of both MTB and rifampin resistance mutations, which are markers for MDR strain
On-demand capability that empowers physicians to manage patients effectively
Excellent Negative Predictive Value keeps TB negative patients from unnecessary and costly respiratory isolations
In 2015, 10.4 million people developed active tuberculosis (TB) (11% of which were HIV positive) and 1.4 million people lost their lives to the disease.1Today, the challenge to the global TB community is to ‘End TB’. The reliance on microscopy, with a sensitivity of only 46%–78%,2 is a severe limitation. Between 36%–59% of pulmonary TB cases are smear-negative/culture-positive and the relative transmission rate (10-24%) of these patients has a strong impact on patient management in hospitals, as well as TB control programs in developed and developing countries.